Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.86 USD

198.86
4,683,324

+2.56 (1.30%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $198.55 -0.31 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre

by Zacks Equity Research

Gilead (GILD) topped earnings and sales expectations in the fourth quarter but the guidance for 2018 was disappointing due to further weakness in the HCV franchise.

    Zacks Equity Research

    Centene (CNC) Beats Q4 Earnings & Revenues, Ups '18 View

    by Zacks Equity Research

    Centene's (CNC) fourth-quarter earnings were hurt by higher selling, general & administrative expenses.

      Zacks Equity Research

      Bristol-Myers (BMY) Beats on Q4 Earnings, Eliquis Impresses

      by Zacks Equity Research

      Bristol-Myers (BMY) beats estimates on both counts in the fourth quarter. Eliquis records solid sales.

        Zacks Equity Research

        The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

        by Zacks Equity Research

        The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex

          Zacks Equity Research

          Amgen (AMGN) Q4 Earnings & Sales Lag, 2018 Sales View Soft

          by Zacks Equity Research

          Amgen (AMGN) misses expectations for both earnings and sales and also issues a lower-than-expected sales guidance for 2018. Shares decline in after-hours trading.

            Zacks Equity Research

            AstraZeneca (AZN) Beats on Q4 Earnings, Guides for 2018

            by Zacks Equity Research

            AstraZeneca (AZN) beats earnings estimates in fourth quarter on higher product revenues.

              Tirthankar Chakraborty headshot

              5 Top Earnings Growth Stocks to Buy in February

              by Tirthankar Chakraborty

              We have shortlisted 5 top-rated stocks that have striking earnings growth and positive estimate revisions.

                Zacks Equity Research

                Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?

                by Zacks Equity Research

                Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.

                  Zacks Equity Research

                  Will Gilead (GILD) Disappoint Investors in Q4 Earnings?

                  by Zacks Equity Research

                  Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.

                    Arpita Dutt headshot

                    Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi

                    by Arpita Dutt

                    While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.

                      Zacks Equity Research

                      Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance

                      by Zacks Equity Research

                      Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.

                        Zacks Equity Research

                        Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View

                        by Zacks Equity Research

                        Anthem (ANTM) reported strong fourth-quarter results on the back of solid performance across its segments.

                          Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton

                          by Zacks Equity Research

                          The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton

                            Zacks Equity Research

                            Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX

                            by Zacks Equity Research

                            Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.

                              Zacks Equity Research

                              HCA Healthcare's (HCA) Q4 Earnings, Revenues Beat Estimates (Revised)

                              by Zacks Equity Research

                              HCA Healthcare's (HCA) strong fourth-quarter results were driven by significant growth in admissions.

                                Zacks Equity Research

                                Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors

                                by Zacks Equity Research

                                Novartis' oncology portfolio gets a further boost with the FDA approval of Lutathera for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.

                                  Zacks Equity Research

                                  Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion

                                  by Zacks Equity Research

                                  Roche announced that it its hemophilia drug Hemlibra obtained a positive opinion from the Committee for Medicinal Products for Human Use in Europe.

                                    Zacks Equity Research

                                    AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III

                                    by Zacks Equity Research

                                    AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.

                                      Zacks Equity Research

                                      Stock Market News for Jan 29, 2018

                                      by Zacks Equity Research

                                      All the three key U.S. indexes closed at record levels on Friday following better-than-expected earnings from Intel, AbbVie and Honeywell

                                        Zacks Equity Research

                                        Strength Seen in AbbVie (ABBV): Stock Soars 13.8%

                                        by Zacks Equity Research

                                        AbbVie (ABBV) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.

                                          Arpita Dutt headshot

                                          AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call

                                          by Arpita Dutt

                                          With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.

                                            Zacks Equity Research

                                            AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up

                                            by Zacks Equity Research

                                            AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

                                              Zacks Equity Research

                                              A Spate of Q4 Earnings

                                              by Zacks Equity Research

                                              A Spate of Q4 Earnings

                                                Mark Vickery headshot

                                                Q4 GDP Sub-3%, Q4 Earnings Roll On

                                                by Mark Vickery

                                                The first read for Q4 GDP reached 2.6%, lower than the consensus estimate of 2.9%.

                                                  Zacks Equity Research

                                                  AbbVie (ABBV) Q4 Earnings & Revenues Beat, Guidance Raised

                                                  by Zacks Equity Research

                                                  AbbVie's (ABBV) fourth-quarter 2017 earnings surpassed estimates with revenues marginally beating the same. Sales of its lead marketed drug Humira also increased compared with the year ago figure.